BeyondSpring’s (NASDAQ:BYSI) lock-up period is set to expire on Tuesday, September 5th. BeyondSpring had issued 174,286 shares in its initial public offering on March 9th. The total size of the offering was $3,485,720 based on an initial share price of $20.00. After the expiration of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Several brokerages have issued reports on BYSI. Maxim Group began coverage on BeyondSpring in a research note on Tuesday, August 22nd. They issued a “buy” rating and a $52.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of BeyondSpring in a report on Monday, August 21st. Zacks Investment Research upgraded BeyondSpring from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Finally, Rodman & Renshaw boosted their price objective on BeyondSpring from $43.00 to $50.00 and gave the company a “buy” rating in a report on Friday, July 14th.

COPYRIGHT VIOLATION WARNING: This piece was reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at

BeyondSpring (NASDAQ:BYSI) opened at 40.59 on Friday. The company’s market cap is $927.24 million. BeyondSpring has a 52 week low of $16.55 and a 52 week high of $48.49. The firm has a 50-day moving average price of $39.45 and a 200-day moving average price of $31.92.

A hedge fund recently bought a new stake in BeyondSpring stock. Tanaka Capital Management Inc. bought a new stake in shares of BeyondSpring Inc. (NASDAQ:BYSI) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring comprises approximately 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th largest position. Tanaka Capital Management Inc. owned 0.10% of BeyondSpring as of its most recent SEC filing. Institutional investors own 1.23% of the company’s stock.

About BeyondSpring

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.